MediPharm Labs Past Earnings Performance
Past criteria checks 0/6
MediPharm Labs has been growing earnings at an average annual rate of 7.8%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 32.8% per year.
Key information
7.8%
Earnings growth rate
21.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | -32.8% |
| Return on equity | -26.1% |
| Net Margin | -30.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How MediPharm Labs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 39 | -12 | 20 | 0 |
| 30 Jun 24 | 38 | -13 | 21 | 0 |
| 31 Mar 24 | 37 | -14 | 23 | 0 |
| 31 Dec 23 | 33 | -13 | 20 | 0 |
| 30 Sep 23 | 30 | -16 | 23 | 0 |
| 30 Jun 23 | 28 | -20 | 22 | 1 |
| 31 Mar 23 | 23 | -26 | 21 | 1 |
| 31 Dec 22 | 22 | -30 | 24 | 1 |
| 30 Sep 22 | 22 | -46 | 32 | 2 |
| 30 Jun 22 | 20 | -46 | 32 | 2 |
| 31 Mar 22 | 21 | -48 | 32 | 1 |
| 31 Dec 21 | 22 | -55 | 31 | 2 |
| 30 Sep 21 | 22 | -64 | 22 | 2 |
| 30 Jun 21 | 22 | -72 | 23 | 1 |
| 31 Mar 21 | 30 | -63 | 25 | 2 |
| 31 Dec 20 | 36 | -66 | 28 | 2 |
| 30 Sep 20 | 62 | -39 | 35 | 2 |
| 30 Jun 20 | 101 | -20 | 35 | 2 |
| 31 Mar 20 | 118 | -15 | 33 | 2 |
| 31 Dec 19 | 129 | 2 | 31 | 1 |
| 30 Sep 19 | 107 | 1 | 22 | 0 |
| 30 Jun 19 | 64 | -4 | 17 | 0 |
| 31 Mar 19 | 32 | -8 | 12 | 0 |
| 31 Dec 18 | 10 | -8 | 6 | 0 |
| 30 Sep 18 | 0 | -6 | 4 | 0 |
| 30 Jun 18 | 0 | -4 | 3 | 0 |
| 31 Mar 18 | 0 | -2 | 2 | 0 |
| 31 Dec 17 | 0 | -1 | 1 | 0 |
Quality Earnings: MLZ is currently unprofitable.
Growing Profit Margin: MLZ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MLZ is unprofitable, but has reduced losses over the past 5 years at a rate of 7.8% per year.
Accelerating Growth: Unable to compare MLZ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MLZ is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: MLZ has a negative Return on Equity (-26.09%), as it is currently unprofitable.